Compare Heron Therapeutics Inc (HRTX) vs KKR & Co Inc (KKR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs KKR & Co Inc — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while KKR & Co Inc trades at $91.07 (market cap $80.39B). The key difference: KKR & Co Inc is far larger — about 1182× Heron Therapeutics Inc's market cap, and KKR & Co Inc pays a 0.87% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and KKR & Co Inc for 67 Days on average.
| HRTX | KKR | |
|---|---|---|
Market Cap | $68.01M | $80.39B |
Volume | 1,891,941 | 6,517,705 |
Sector | Health | Financials |
52-Week High | $1.49 | $142.75 |
52-Week Low | $0.27 | $83.88 |
Typical Hold Time | 35 Days | 67 Days |
Enterprise Value | $174.75M | $2.95B |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3967, up 1.72% today, with a bullish technical signal from moving averages but mixed earnings. The company reported a net loss of $20.20 million in 2025, with revenue of $154.90 million, and has a high gross margin of 70.07% but negative profitability metrics. Recent Q2 2026 results missed EPS estimates, though Q4 2025 beat expectations. Analyst consensus is strongly bullish with 17 buy ratings.
The outlook is cautious due to persistent losses and cash burn, but strong analyst support and a low P/S ratio of 0.44 may appeal to value investors. Key risks include ongoing unprofitability and competitive pressures in the biotech sector. Investors should weigh the high institutional optimism against fundamental challenges.
KKR trades at $90.95, up 1.43% on the day, with strong analyst support showing 24 buy ratings and a $123.30 consensus price target. Recent earnings beat expectations in Q1 and Q2 2026, though Q4 2025 missed. Technical indicators are bearish overall, with RSI levels suggesting potential oversold conditions. The company maintains solid profitability with 14.97% net income margin and continues active portfolio management through recent acquisitions and divestitures.
The investment case for KKR appears favorable given the significant upside to analyst targets and strong institutional support. However, investors face risks from volatile cash flows, high debt levels, and market-sensitive revenue streams. The upcoming Q3 2026 earnings report on November 9 will be crucial for validating current valuation metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
